H.C. Wainwright analyst Joseph Pantginis downgraded Aravive to Neutral from Buy without a price target after the company announced that the registration-directed Phase 3 trial of the company’s GAS6-AXL pathway inhibitor, batiraxcept, in combination with chemotherapy for platinum-resistant ovarian cancer did not meet its primary endpoint of progression-free survival. The analyst believes the perceived risk for the company’s renal cell and pancreatic programs has increased significantly.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ARAV: